A federal jury in the United States has found that Pfizer violated anti-racketeering laws in promoting its epilepsy drug Neurontin for unapproved uses and must pay at least US$142 million ($201 million) in damages.
The jury sided with California-based Kaiser Foundation Health Plan and Kaiser Foundation Hospitals, the first to try a Neurontin case against the drugmaker.
Kaiser claimed it was misled into believing Neurontin was effective for off-label treatment of migraines, bipolar disorder and other conditions.
Pfizer argued that Kaiser physicians still recommend the drug for those uses.
Drug company fined $201m
AdvertisementAdvertise with NZME.
